JOE
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Journal of Endocrinology (2000) 165, 123-131       DOI: 10.1677/joe.0.1650123
© 2000 Society for Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (23)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Puglianiello, A
Right arrow Articles by Cianfarani, S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Puglianiello, A
Right arrow Articles by Cianfarani, S
Journal of Endocrinology, Vol 165, Issue 1, 123-131
Copyright © 2000 by Society for Endocrinology


Articles

IGF-I stimulates chemotaxis of human neuroblasts. Involvement of type 1 IGF receptor, IGF binding proteins, phosphatidylinositol-3 kinase pathway and plasmin system

A Puglianiello, D Germani, P Rossi, and S Cianfarani


SH-SY5Y human neuroblastoma cells express IGF receptors, IGFs and IGF binding proteins (IGFBPs), and provide a model for studying the role of the IGF system in human neuronal development. We investigated the effect of IGF-I and des(1-3)IGF-I on the motility of SH-SY5Y cells by a cell migration assay based on the assessment of the number of cells which migrated across 8 microm pore size membranes and around an agarose drop. IGF-I and des(1-3)IGF-I stimulated neuroblast chemotaxis in a dose-dependent manner. Treatment of cells with these agents for 24 h resulted in a significant increase (IGF-I by 70% and des(1-3)IGF-I by 90%; P<0. 0001) in cell motility relative to control conditions. Addition of monoclonal antibody against type 1 IGF receptor (alpha-IR3), significantly (P<0.05) reduced the cell motility induced by IGF-I (by 30%) and des(1-3)IGF-I (by 70%). Wortmannin, a specific inhibitor of phosphatidylinositol (PI)-3 kinase intracellular signalling, also reduced the IGF-stimulated cell migration (by over 40%, P<0.01), indicating a key role of the PI-3 kinase pathway in mediating the IGF effect on neuroblast migration. Finally, cell treatment with plasminogen (PLG) markedly enhanced neuroblast migration (by over 200%, P<0.01), whereas incubation with the PLG inhibitor 4-(2-aminoethyl)-benzenesulphonyl fluoride reduced cell motility (by 80%, P<0.01), thus suggesting an involvement of PLG-dependent IGFBP proteolysis in the regulation of neuroblast motility. In conclusion, IGF-I is a potent stimulator of neuroblast migration through the activation of type 1 IGF receptor and the PI-3 kinase intracellular pathway. IGFBPs and the plasmin system seem to play a role in cell motility, although the nature and the extent of their involvement has yet to be elucidated.


This article has been cited by other articles:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
T. Fujiyoshi, K. Hirano, M. Hirano, J. Nishimura, S. Takahashi, and H. Kanaide
Plasmin Induces Endothelium-Dependent Nitric Oxide-Mediated Relaxation in the Porcine Coronary Artery
Arterioscler Thromb Vasc Biol, April 1, 2007; 27(4): 949 - 954.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. M. van Golen, T. S. Schwab, B. Kim, M. E. Soules, S. Su Oh, K. Fung, K. L. van Golen, and E. L. Feldman
Insulin-Like Growth Factor-I Receptor Expression Regulates Neuroblastoma Metastasis to Bone.
Cancer Res., July 1, 2006; 66(13): 6570 - 6578.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
T. W. Bauer, R. J. Somcio, F. Fan, W. Liu, M. Johnson, D. P. Lesslie, D. B. Evans, G. E. Gallick, and L. M. Ellis
Regulatory role of c-Met in insulin-like growth factor-I receptor-mediated migration and invasion of human pancreatic carcinoma cells.
Mol. Cancer Ther., July 1, 2006; 5(7): 1676 - 1682.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
V. C. Russo, P. D. Gluckman, E. L. Feldman, and G. A. Werther
The Insulin-Like Growth Factor System and Its Pleiotropic Functions in Brain
Endocr. Rev., December 1, 2005; 26(7): 916 - 943.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
D. L. Hunton, W. G. Barnes, J. Kim, X.-R. Ren, J. D. Violin, E. Reiter, G. Milligan, D. D. Patel, and R. J. Lefkowitz
{beta}-Arrestin 2-Dependent Angiotensin II Type 1A Receptor-Mediated Pathway of Chemotaxis
Mol. Pharmacol., April 1, 2005; 67(4): 1229 - 1236.
[Abstract] [Full Text] [PDF]


Home page
JCBHome page
L. S. Harrington, G. M. Findlay, A. Gray, T. Tolkacheva, S. Wigfield, H. Rebholz, J. Barnett, N. R. Leslie, S. Cheng, P. R. Shepherd, et al.
The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins
J. Cell Biol., July 19, 2004; 166(2): 213 - 223.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Silva, A. Beckedorf, and E. Bieberich
Osteoblast-derived Oxysterol Is a Migration-inducing Factor for Human Breast Cancer Cells
J. Biol. Chem., July 3, 2003; 278(28): 25376 - 25385.
[Abstract] [Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the Society for Endocrinology.